Study identifies mutations outside of traditional vaccine targets as barrier to vaccine development – Johns Hopkins Medicine Unlike its viral cousins hepatitis A and B, hepatitis C virus (HCV) has eluded the development of a vaccine and infected more than 170 million people worldwide. Now, researchers at Johns Hopkins Medicine report that a novel laboratory tool that lets them find virus mutations faster and more efficiently than ever before has ident
Virus induces liver cells to make molecules that inhibit production of a key immune signaling receptor. The virus that causes hepatitis C protects itself by blocking signals that call up immune defenses in liver cells, according to University of Washington researchers and colleagues reporting Nov. 14 in Nature Medicine. "The finding helps explain why many patients fail certain drug treatments, and should help develop more effective alternate treatm
Reovirus, a common virus that causes mild cases of respiratory infection, mainly in children, could be harnessed as an immunotherapy to fight primary liver cancer and hepatitis C. Viruses cause around 20% of all human cancer. While only a handful are known to be tumour-promoting, this is a particular problem for liver cancer, where around three-quarters of cases are caused by either hepatitis C virus (HCV) or hepatitis B virus (HBV). These cause long-live
ATLANTA, GA and BOTHELL, WA -- (Marketwired) -- 11/07/16 -- Cocrystal Pharma, Inc. (OTCQB: COCP), announced positive data from a randomized, double-blind Phase Ia/Ib study of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor (NNI), for the treatment of chronic hepatitis C virus (HCV) infection. The study is designed to evaluate CC-31244's safety/tolerability and pharmacokinetics, including food effect and antiviral activity. The study includ
Alternative forms of two genes are associated with a boost in immunity to hepatitis C after childbirth, a study led by a Nationwide Children's Hospital physician-researcher shows. At three months postpartum, the number of viruses circulating in the blood declined sharply in most women who carried particular versions of IFNL3 and HLA-DPB1 genes. Mothers lacking these gene variants experienced little change in viral levels after delivery. The research is
WASHINGTON -- Some patients facing a years-long wait for a kidney transplant are jumping ahead in line thanks to a startling experiment: They're agreeing to an organ almost sure to infect them with hepatitis C. Knowingly transmitting a dangerous virus may sound drastic, but two leading transplant centres are betting the strategy will save lives, if new medications that promise to cure hepatitis C allow use of organs that today go to waste. Pilot studie
Scripps Research Institute La Jolla, CA -- Oct. 24, 2016 -- Researchers have been trying for decades to develop a vaccine against the globally endemic hepatitis C virus (HCV). Now scientists at The Scripps Research Institute (TSRI) have discovered one reason why success has so far been elusive. Using a sophisticated array of techniques for mapping tiny molecular structures, the TSRI scientists analyzed a lab-made version of a key viral protein, which
Research into how horses manage to naturally eliminate a liver virus related to the hepatitis C virus from their system has the potential ultimately benefit humans, according to researchers. Equine hepacivirus (EHCV) is the closest known relative to hepatitis C virus. The hepatitis C virus causes a blood-borne infectious liver disease affecting an estimated 2.7 to 3.9 million people in the United States, according to the Centers for Disease Control and
Researchers have discovered a possible new and inexpensive tool to fight hepatitis C virus (HCV) infection: quercetin, a natural flavonoid. The substance is sold as an herbal supplement and is found in many plants and foods, including red wine, onions, green tea, apples, and berries. A study describing research conducted by Angela Rojas of UCM Digestive Diseases, Virgen Macarena-Virgen del Rocio University Hospitals in Seville, Spain, and colleagues ...
In just the last few years, new medications have turned hepatitis C into a widely and quickly curable disease — for those who can afford it. But the lesser-known origins of the story trace back to a 1990s laboratory invention that made it all possible. Now, two virologists who pioneered that pivotal development, and a drug researcher who created the first revolutionary drug, are being honored with one of the most prestigious awards in medical science.